Sign in
Taking people in United StatesEarly phase 1

Siplizumab injections for hidradenitis suppurativa, a painful skin condition

Tests siplizumab given under the skin in adults with hidradenitis suppurativa.

Key facts

Who runs it
University of Alabama at Birmingham
Where
Birmingham, United StatesSee the site
Trial code
Registry title
Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.
Status
Recruiting
Phase
Early phase 1
People taking part
12 people, planned
Started
9 May 2025
Expected to end
31 Jul 2028
Type of study
Interventional, 3 groups
Treatments tested
  • Siplizumab
Record updated
1 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with moderate to severe hidradenitis suppurativa (HS), a long-term skin disease with painful lumps. Standard treatments have not worked for them. The trial tests siplizumab injections under the skin.

Age
18 years and older
Sex
Male and female
Disease stage
Moderate to severe HS, Hurley stage II or III, for at least 6 months. It has not responded to conventional therapies. A total AN count (number of abscesses and inflamed lumps) of 5 or more. No more than 20 draining fistulas (draining tunnels under the skin).
Earlier treatment
At least 1 course of oral antibiotics for HS must have failed, or could not be taken. No biologic drugs or other study drugs in the 3 months before the start. No non-biologic HS treatments, other than antibiotics or hormone therapy, in the 4 weeks before. No new oral antibiotics or hormone therapy in the 6 weeks before. A steady dose of doxycycline or tetracycline for at least 6 weeks is allowed. No kenalog injections into the lesions in the 2 weeks before.
Biomarker or test result
Negative tuberculosis (TB) test (Quantiferon Gold, T-spot) within 3 months before screening. People with past latent TB must be on treatment or have finished it within 5 years. Blood tests must be within set limits, for example platelets of at least 150,000 /μL and hemoglobin of at least 10 g/dL.

Main reasons for not taking part

  • Cancer now or in the past 5 years, except treated non-melanoma skin cancer or cervical carcinoma in situ
  • Known HIV, hepatitis B or hepatitis C infection
  • Pregnancy, breastfeeding, or planning a pregnancy during the study
  • Ongoing, chronic or recurrent infections, or a positive SARS-CoV-2 test
  • Past allergic reaction to siplizumab or its ingredients

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Male or Female at least 18 years of age, and provide informed consent prior to study procedures
  • Have moderate to severe HS classified as Hurley stage II or III for at least 6 months refractory to conventional therapies with a total AN count of greater than or equal to 5 prior to enrollment/randomization
  • Failed at least 1 course of oral antibiotics for treatment of HS (or demonstrated intolerance to, or had a contraindication to oral antibiotics for treatment of their HS)
  • Women of Childbearing potential must have a urine pregnancy test at screening, wk 0 and prior to administration of the study medication
  • Women of childbearing potential must be willing to continue a highly effective method of birth control throughout the study (oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device or intrauterine system; barrier methods: condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal foam/gel/film/cream/suppository (if available in their locale); male partner sterilization (the vasectomized partner should be the sole partner for that participant); true abstinence (when this is in line with the preferred and usual lifestyle of the participant)
  • Negative screening for tuberculosis (TB) (Quantiferon Gold, T-spot) within 3 months prior to screening
  • If a positive history of latent tuberculosis:; Currently receiving treatment for latent TB per standard of care; Have documentation of having completed treatment within 5 years prior to baseline
  • Agree not to have a live vaccination during the study

Who cannot take part

  • Have greater than 20 draining fistulas at screening or Day 1 prior to enrollment/randomization
  • Receipt of non-biologic treatments for HS within 4 weeks prior to baseline other than antibiotics or hormonal therapy
  • Receipt of biologic agents within 3 months prior to baseline
  • Receipt of any other investigational product within 3 months prior to baseline
  • Receipt of new oral antibiotics or hormonal therapy within 6 weeks prior to baseline; Subjects may be included if they are on steady dose of doxycycline or tetracycline antibiotics only for at least 6 weeks prior to baseline visit and may not change or discontinue dose during course of study
  • Receipt of intralesional kenalog injections within 2 weeks prior to baseline
  • Previous hypersensitivity reaction to siplizumab or to any of the components
  • Underlying condition (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal) which in the opinion of the investigator significantly immunocompromises the subject and/or places the subject at unacceptable risk for receiving an immunomodulatory therapy
  • Any other active skin disease that in the opinion of the investigator would interfere with the assessment of HS
  • Any uncontrolled diagnosis or condition that in the opinion of the investigator will interfere with the assessments or the study
  • Currently has a malignancy or a history of a malignancy within 5 years before screen (except successfully treated non-melanoma skin cancer or cervical carcinoma in situ)
  • History of an ongoing, chronic or recurrent infectious disease
  • Known infection with HIV, hepatitis B or hepatitis C at screening or randomization; Patients who are Hepatitis B Core antibody and/or Hep B Surface Antigen positive will be excluded from this study. Patients who are Hepatitis C ab positive will also be excluded from this study
  • Any of the following laboratory abnormalities within 30 days of enrollment:; White blood count (WBC) < 3 x 103/μL;,; CD4+ count below the lower limit of normal,; Platelet count < 150,000 /μL,; Hemoglobin < 10 g/dL,; ALT ≥ 2x upper limit of normal (ULN) or; AST ≥ 2x ULN; Serum creatinine >1.5x ULN in adults; Positive molecular testing of SARS-CoV-2; ALC less than 800 lymphocytes/mm3
  • Are currently pregnant, breastfeeding, or planning to get pregnant during the study

Where in United States

  • University of Alabama at BirminghamBirmingham, United StatesContact: Ralee' B Bunt, MSPHTaking people

About the trial

What the trial wants to find out

This study is to investigate the efficacy of siplizumab in the treatment of Hidradenitis Suppurativa.

The 3 groups in the trial

  • siplizumab 10mgTreatment being tested

    Up to 6 participants may receive a 10 mg subcutaneous dose of siplizumab from week 0 to week 4 then at weeks 6 and 8.

    Treatment: Siplizumab

  • siplizumab 20mgTreatment being tested

    Up to 6 participants may receive a 20 mg subcutaneous dose of siplizumab from week 0 to week 4 then at weeks 6 and 8.

    Treatment: Siplizumab

  • siplizumab 40mgTreatment being tested

    Up to 6 participants may receive a 40 mg subcutaneous dose of siplizumab from week 0 to week 4 then at weeks 6 and 8.

    Treatment: Siplizumab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open-label Parallel Group Pilot Study to Demonstrate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa
Plain-language title
Siplizumab injections for hidradenitis suppurativa, a painful skin conditionGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
1 September 2026